Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.

D. Pastore, B. Bruno, P. Carluccio, M. S. De Candia, S. Mammoliti, C. Borghero, A. Chierichini, F. Pavan, M. Casini, M. Pini, L. Nassi, R. Greco, F. P. Tambaro, P. Stefanoni, G. Console, F. Marchesi, L. Facchini, A. Mussetti, M. Cimminiello, F. SaglioD. Vincenti, S. Falcioni, P. Chiusolo, J. Olivieri, A. Natale, M. Faraci, S. Cesaro, S. Marotta, A. Proia, I. Donnini, D. Caravelli, E. Zuffa, A. P. Iori, E. Soncini, V. Bozzoli, G. Pisapia, R. Scalone, O. Villani, A. Prete, A. Ferrari, M. Menconi, G. Mancini, F. Gigli, G. Gargiulo, Barbara Bruno, F. Patriarca, F. Bonifazi

Research output: Contribution to journalArticlepeer-review

Abstract

A survey within hematopoietic stem cell transplant (HSCT) centers of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) was performed in order to describe current antiemetic prophylaxis in patients undergoing HSCT. The multicenter survey was performed by a questionnaire, covering the main areas on chemotherapy-induced nausea and vomiting (CINV): antiemetic prophylaxis guidelines used, antiemetic prophylaxis in different conditioning regimens, and methods of CINV evaluation. The survey was carried out in November 2016, and it was repeated 6 months after the publication of the Multinational Association of Supportive Care in Cancer (MASCC)/European Society for Medical Oncology (ESMO) specific guidelines on antiemetic prophylaxis in HSCT. The results show a remarkable heterogeneity of prophylaxis among the various centers and a significant difference between the guidelines and the clinical practice. In the main conditioning regimens, the combination of a serotonin(3) receptor antagonist (5-HT3-RA) with dexamethasone and neurokin(1) receptor antagonist (NK1-RA), as recommended by MASCC/ESMO guidelines, increased from 0 to 15% (before the publication of the guidelines) to 9-30% (after the publication of the guidelines). This study shows a lack of compliance with specific antiemetic guidelines, resulting mainly in under-prophylaxis. Concerted strategies are required to improve the current CINV prophylaxis, to draft shared common guidelines, and to increase the knowledge and the adherence to the current recommendations for CINV prophylaxis in the specific field of HSCT.
Original languageEnglish
Pages (from-to)867-875
Number of pages9
JournalAnn. Hematol.
Volume99
Issue number4
DOIs
Publication statusPublished - 2020

Keywords

  • prevention
  • american-society
  • Antiemetic prophylaxis
  • aprepitant
  • chemotherapy
  • chemotherapy-induced nausea
  • CINV
  • double-blind
  • ESMO guidelines
  • Hematology
  • Hematopoietic stem cell transplantation
  • high-dose melphalan
  • highly emetogenic
  • MASCC
  • multiple-myeloma
  • phase-iii
  • triple-drug combination

Fingerprint

Dive into the research topics of 'Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs.'. Together they form a unique fingerprint.

Cite this